News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Anita Afzali: Ozanimod for moderate to severe ulcerative colitis
Photo taken from Anita Afzali/X
Jun 8, 2024, 02:27

Anita Afzali: Ozanimod for moderate to severe ulcerative colitis

Anita Afzali, Executive Vice Chair of the University of Cincinnati College of Medicine, shared a post on X:

“Our Pub Alert – Ozanimod for moderate to severe ulcerative colitis in patients naive to advanced therapies
Take a read.”

Anita Afzali

Read further.
Source: Anita Afzali/X 

Anita Afzali cancer OncoDaily Oncology ulcerative colitis
Special Coverage
Science
Apr 26, 2025, 10:52
Nat Lester-Coll: The role of PSMA PET imaging
Science
Apr 26, 2025, 10:37
Elli Papaemmanuil: Tumor-Infiltrating Clonal Hematopoiesis
Blog
Apr 26, 2025, 10:18
Renowned Leader William N. Hait Appointed as Chief Scientific Advisor of the AACR
Science
Apr 26, 2025, 09:19
Myeloma Paper of the Day, April 26th, suggested by Robert Orlowski
Societies
Apr 26, 2025, 08:02
10 Caring Notes from Pope Francis on Healthcare
Blog
Apr 26, 2025, 05:35
St. Baldrick's Foundation - Celebrating Our Volunteer Barbers: Bringing Hope, One Haircut at a Time
Blog
Apr 26, 2025, 05:30
Duke Radiation Oncology - Erik Sulman Named Chair of Radiation Oncology at Duke University School of Medicine
Blog
Apr 26, 2025, 05:17
Bernard A. Fox: Heading to AACR2025 to talk about our work on cancer immunotherapy for HNSCC
Blog
Apr 26, 2025, 05:03
Katsuaki Maehara: CXCL13-Reprogrammed Macrophages Drive Cancer-Associated Pulmonary Embolism
Blog
Apr 26, 2025, 04:56
Peter Pisters: MD Anderson Cancer Center Experts Lead the Way at AACR2025
Opinion
Apr 26, 2025, 03:09
Annual Report to the Nation on the Status of Cancer - NCI Division of Cancer Control and Population Sciences
Insight
Apr 26, 2025, 00:43
Navneet Majhail: Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring